Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$11.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
What isRosuvastatin (5mg) used for: Rosuvastatin is a medication primarily used to treat high cholesterol. It contains a blend of cholesterol-lowering ingredients, which are collectively known as " statins". Rosuvastatin is a statin type II inhibitor, used to lower LDL cholesterol levels by inhibiting the hepatic cholesterol synthesis. This reduction in cholesterol synthesis leads to a decrease in the amount of free cholesterol found in the liver. Rosuvastatin is typically taken daily as a 5mg oral tablet, which can be taken with or without food. Rosuvatin is available in various strengths, including 10mg, 20mg, and 40mg. Rosuvastatin is a widely used lipid-lowering agent, often used to reduce high blood cholesterol levels.What is the difference between Rosuvastatin (5mg) and Crestor (Rx)? Rosuvastatin (5mg) is a medication primarily used to treat high cholesterol. Rosuvastatin is a lipid-reducing agent commonly used to reduce high cholesterol levels in adults and may also be used in adults and children aged 12 years and older to reduce the risk of cardiovascular events such as heart attacks and strokes. Rosuvastatin is typically used to lower triglycerides in the blood, as well as reduce the risk of high blood pressure. Rosuvastatin is available in various strengths, including 10mg, 20mg, and 40mg. Rosuvastatin is a statin type II inhibitor, commonly used to lower high cholesterol levels in adults and may also be used in adults and children aged 12 years and older. Rosuvastatin is typically used to reduce the risk of cardiovascular events in adults and may also be used in adults and children aged 12 years and older.What is the difference between Lipitor (�1mg) and Crestor (Crestor XR)? Lipitor (�1mg) and Crestor (Crestor XR) are dual-acting medications, designed to manage high cholesterol and reduce the risk of cardiovascular events. By blocking cholesterol absorption, Lipitor and Crestor both reduce the risk of developing cardiovascular events and can be used in conjunction with diet and exercise to achieve the same results. Because Lipitor and Crestor both work by inhibiting the enzyme which is responsible for breaking down triglycerides, they have been found to be safe and effective in treating both high and low levels of high-sodium coronary heart disease (CHD) in patients.Lipitor (Oral Tablet) is a generic medication containing the same active ingredient as Lipitor (Lipitor), but at a lower dose. Both Lipitor (Oral Tablet) and Crestor (Crestor XR) work by inhibiting the enzyme which is responsible for breaking down triglycerides, thereby reducing the risk of developing high levels of high-sodium coronary heart disease (CHD). By reducing the amount of triglycerides in the blood, Lipitor and Crestor promote a lowering of blood pressure. Rosuvastatin (Oral Tablet) can be taken with or without food and is generally well-tolerated with few reported side effects.
Crestor is a prescription medication used to lower cholesterol and triglycerides in the blood. It is a statin treatment to reduce high cholesterol and low blood pressure in patients with heart failure. It reduces the risk of stroke in people with heart failure.
Crestor works in the liver and kidneys is used to treat heart failure and reduces attacks and strokes in people with heart failure.
Rosuvastatin is used to treat heart failure and reduce symptoms like shortness of breath, swelling in the legs, shortness of color, weakness and dizziness in people with heart failure. Rosuvastatin is also used to treat high cholesterol in people with high cholesterol who are at increased risk of heart failure complications. Crestor is used along with a reduced-cholesterol diet to help lower cholesterol in people with high cholesterol who are at risk of heart problems. Talk to your doctor if you have any medical conditions.
Take Crestor by mouth with or without food. Do not take Crestor more than 4 hours apart. You must take Crestor 60 minutes before a meal to reduce the risk of stomach upset.
Like other medications, you may experience side effects, although not everyone experiences it. Side effects are usually mild or mild depending on the severity of the heart failure treatment.
Common side effects of Crestor include headache, nausea, diarrhea, indigestion, stomach pain, constipation, dry mouth, rarely will missed meals, and dizziness. More than 1 in 100 people experiences a side effect. You may experience side effects in less than 1 in 100 people but they are common and often bother you.
Serious side effects include hearing problems, heart attack, stroke, irregular heartbeat, high blood pressure, bleeding problems, blood clots, and kidney problems. Serious side effects include an increased risk of stroke, blood clots, and high blood potassium levels.
You can buy Crestor online without a prescription at Trust Pharmacy or from community pharmacy. You will have an easy to access, effortless job search for hours a week is time-consuming.
You can find Crestor online at online clinic from the comfort of your own home. It is only by joining a community drugstore, pharmacist, and online clinics and health care providers that you can learn more about each clinic, health care service, and health plan.
Common side effects of Crestor include drowsiness, dizziness, decreased sex drive, feeling sick, and blurred vision.
You can experience side effects in less than 1% of people on Crestor.
You may also experience side effects in less than 1 in 100 people.
You should not take Crestor if you are allergic to rosuvastatin, or liver, heart, kidney, or blood vessel disease. Your doctor may want you to see a doctor if you have any of the following:
Visit Crestor for more details.
You can take Crestor with or without food.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$12.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Keep out of the reach of childrenRead all product information BaiyuningHealthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews are taken from various sources while the packaging is being addressed to the product and strive to provide terminated product immediately for consumer demand.
Medicare$2.50
£5.90
$47.
AstraZeneca (AZ) today announced the approval of AstraZeneca’s cholesterol drug Crestor (simvastatin) for primary and secondary prevention in the United States. The approval is the first indication for Crestor to treat patients with primary or secondary hypercholesterolemia and for treatment of LDL-C or high-sensitivity C-reactive protein (hs-CRP). The company expects to achieve its goal of achieving its primary prevention goals in the fourth quarter of 2009.
As part of AstraZeneca’s ongoing effort to develop a new drug to improve overall cholesterol control, Crestor is the first new agent to be approved to treat primary hypercholesterolemia.
In its pre-marketing review of Crestor data, the company noted that the primary prevention and secondary prevention results achieved by this new agent are not consistent with the established clinical trial results.
“This new agent, in conjunction with our existing primary prevention studies, will not have a high probability of causing clinically significant LDL-C elevations,” said Dr. Sidney Wolfe, director of the Public Citizen Center for Disease Control and Prevention. “We also believe that this new agent is the most effective agent to prevent primary hypercholesterolemia in the United States.”
Crestor is currently being evaluated for the primary prevention in patients with primary hypercholesterolemia, based on the results of a secondary study of patients with primary hypercholesterolemia. The trial was designed to demonstrate the safety and effectiveness of the new agent, and a primary prevention trial was conducted to evaluate the effectiveness of the new agent.
Crestor’s primary prevention results were consistent with those achieved in the primary prevention trial, with the primary prevention achieved in patients with LDL-C of at least 60 mg/dL or higher and the secondary prevention achieved in patients with LDL-C of more than 60 mg/dL or higher, and with the primary prevention achieved in patients with LDL-C of less than 60 mg/dL or higher.
The results of the primary prevention study were also consistent with those achieved in the secondary prevention trial, with the secondary prevention achieved in patients with LDL-C of at least 60 mg/dL or higher and the secondary prevention achieved in patients with LDL-C of more than 60 mg/dL or higher. The secondary prevention results were also consistent with those achieved in the primary prevention trial.
“Crestor is an important and highly effective treatment for patients with primary hypercholesterolemia,” said AstraZeneca.
“We are excited about our new agent for primary prevention and look forward to further development and approval of Crestor in the United States in the second half of 2009. Our primary prevention results have been consistent with those achieved in our secondary prevention trials,” said AstraZeneca.
In addition, AstraZeneca expects to achieve the secondary prevention goals of maintaining LDL-C, cholesterol-lowering therapy LDL-C/HDL-C and reducing the risk of cardiovascular disease in patients with primary hypercholesterolemia. The company expects to achieve the secondary prevention goals in patients with primary hypercholesterolemia in the third quarter of 2009.
In the first two years of the new Crestor indication, Crestor will be indicated for the primary prevention of patients with hypercholesterolemia in the United States. The primary prevention will be a trial with LDL-C and HbA1c as primary measures to measure the effectiveness of Crestor in this population.
“This is the first indication for a new Crestor indication for primary hypercholesterolemia,” said AstraZeneca. “The clinical benefit from this new indication for primary hypercholesterolemia is the ability to reduce the risk of cardiovascular disease, and thus improve overall cardiovascular safety. This new indication for primary hypercholesterolemia is very important for our ability to continue to achieve this goal.”
The approval of the new Crestor indication will enable AstraZeneca to bring to market a new, clinically proven and more effective cholesterol-lowering therapy for primary hypercholesterolemia, according to a statement to The Canadian Press. The company will also begin to market an additional cholesterol-lowering therapy in the United States in the second half of 2009. This will also enable AstraZeneca to obtain FDA approval to market a new, clinically proven and more effective cholesterol-lowering therapy for primary hypercholesterolemia.
Stade de France Pharmacy